We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Doxorubicin hydrochloride injection, BP 50 mg/25 mL (2mg/mL) isotonic sterile solution in single use vial (Accord, Canada)
Section 19A approved medicine
Doxorubicin hydrochloride injection, BP 50 mg/25 mL (2mg/mL) isotonic sterile solution in single use vial (Accord, Canada)
Section 19A approval holder
Accord Healthcare Pty Ltd ABN 49 110 502 513
Phone
1800 222 673
Approved until
Status
Current
Medicines in short supply/unavailable
DOXORUBICIN ACCORD doxorubicin hydrochloride 200 mg/100 mL concentrated solution for injection vial - ARTG 174248
Indication(s)
To produce regression in neoplastic conditions such as: acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both Hodgkin's and non-Hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc.
Doxorubicin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder. (Tis, T1, T2).
Images
